| scholarly article | Q13442814 |
| P356 | DOI | 10.1210/JC.84.6.1966 |
| P698 | PubMed publication ID | 10372695 |
| P2093 | author name string | Strom BL | |
| Berlin JA | |||
| Snyder PJ | |||
| Holmes JH | |||
| Loh L | |||
| Haddad JG Jr | |||
| Kapoor SC | |||
| Attie MF | |||
| Staley J | |||
| Santanna J | |||
| Dlewati A | |||
| Hannoush P | |||
| Peachey H | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | testosterone | Q1318776 |
| testosterone | Q27863114 | ||
| P304 | page(s) | 1966-1972 | |
| P577 | publication date | 1999-06-01 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Effect of testosterone treatment on bone mineral density in men over 65 years of age. | |
| P478 | volume | 84 |
| Q37641683 | A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel. |
| Q91665299 | A Clinical Perspective of Sleep and Andrological Health: Assessment, Treatment Considerations, and Future Research |
| Q34275005 | A Clinical Trial of 7α-Methyl-19-Nortestosterone Implants for Possible Use as a Long-Acting Contraceptive for Men |
| Q39208990 | A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management |
| Q37531062 | A case series of the safety and efficacy of testosterone replacement therapy in renal failure and kidney transplant patients |
| Q24602168 | A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians |
| Q38510711 | A study of male patients with forearm fracture in Northern Ireland |
| Q39738952 | Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials |
| Q57338554 | Age, obesity and inflammation at baseline predict the effects of testosterone administration on the metabolic syndrome |
| Q35784175 | Age-related changes in testosterone and the role of replacement therapy in older men. |
| Q30625276 | Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort |
| Q46856977 | Alendronate for osteoporosis in men with androgen-repleted hypogonadism |
| Q34207540 | An update on male hypogonadism therapy |
| Q37778223 | Androgen Replacement Therapy in Late-Onset Hypogonadism: Current Concepts and Controversies – A Mini-Review |
| Q43923479 | Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume |
| Q37961162 | Androgen deficiency in aging and metabolically challenged men. |
| Q34707682 | Androgen deficiency in the aging male: when to evaluate and when to treat |
| Q35040385 | Androgen deficiency in the aging male: when, who, and how to investigate and treat |
| Q34695715 | Androgen replacement therapy and prostate safety |
| Q24551170 | Androgen replacement therapy in the aging male |
| Q35871132 | Androgen replacement therapy: present and future |
| Q53341836 | Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. |
| Q34224790 | Androgens and aging |
| Q79811504 | Androgens and bone |
| Q35145586 | Androgens and the ageing male and female |
| Q28352150 | Andropause. Testosterone replacement therapy for aging men |
| Q35573885 | Andropause: To treat or not to treat? |
| Q35563191 | Andropause: an old concept in new clothing |
| Q34511442 | Andropause: clinical implications of the decline in serum testosterone levels with aging in men. |
| Q43586956 | Andropause: is it time for the geriatrician to treat it? |
| Q36103521 | Andropause: is the emperor wearing any clothes? |
| Q46746546 | Andropause: need for concrete guidelines until more evidence becomes available |
| Q35128738 | Aromatase inhibitors in men: effects and therapeutic options |
| Q38380236 | Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial |
| Q37593955 | Associations between gender, age and waist circumference. |
| Q34045842 | Background for studies on the treatment of male osteoporosis: state of the art. |
| Q44655921 | Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. |
| Q36848797 | Biochemical assessment of bone turnover and bone fragility in men. |
| Q38645004 | Body Composition changes with Testosterone Replacement Therapy following Spinal Cord Injury and Aging. A Mini Review. |
| Q36560251 | Bone fragility in men--where are we? |
| Q51776599 | Bulbocavernosus muscle area as a novel marker for hypogonadism. |
| Q37134718 | Causes, consequences, and treatment of osteoporosis in men. |
| Q31099075 | Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials |
| Q51887248 | Clinical practice manual for late-onset hypogonadism syndrome. |
| Q38607545 | Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen |
| Q35156177 | Correlates of trabecular and cortical volumetric bone mineral density of the radius and tibia in older men: the Osteoporotic Fractures in Men Study |
| Q36995628 | Crystallization and preliminary X-ray analysis of the human androgen receptor ligand-binding domain with a coactivator-like peptide and selective androgen receptor modulators. |
| Q40747297 | Determinants of bone density in healthy older men with low testosterone levels |
| Q43603123 | Determinants of bone mineral density in Chinese men. |
| Q35576441 | Diagnosis and Treatment of Low Testosterone among Patients with End-Stage Renal Disease |
| Q36293061 | Diagnosis and management of testosterone deficiency |
| Q37883014 | Differing levels of testosterone and the prostate: a physiological interplay |
| Q35023152 | Double blind randomized placebo-controlled trial on the effects of testosterone supplementation in elderly men with moderate to low testosterone levels: design and baseline characteristics [ISRCTN23688581]. |
| Q46877450 | Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism |
| Q38380241 | Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial |
| Q46459550 | Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. |
| Q55344691 | Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial. |
| Q46583475 | Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study |
| Q34458372 | Effects of Transdermal Testosterone on Bone and Muscle in Older Men with Low Bioavailable Testosterone Levels, Low Bone Mass, and Physical Frailty |
| Q35667571 | Effects of androgen replacement on metabolism and physical performances in male hypogonadism |
| Q37482736 | Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. |
| Q35101799 | Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. |
| Q44991382 | Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease |
| Q33222142 | Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis |
| Q44619585 | Effects of testosterone replacement therapy on bone metabolism in male post-surgical hypogonadotropic hypogonadism: focus on the role of androgen receptor CAG polymorphism |
| Q34540439 | Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM Trial): design and methods |
| Q38473093 | Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial |
| Q45267669 | Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome |
| Q43650554 | Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. |
| Q33943952 | Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels |
| Q37234333 | Effects of transdermal testosterone treatment on inflammatory markers in elderly males |
| Q36271804 | Endocrine and metabolic changes in human aging |
| Q36338679 | Endocrine regulation of bone turnover in men. |
| Q34032252 | Endocrinological aspects of aging in men: is hormone replacement of benefit? |
| Q34543980 | Estrogens and Androgens in Skeletal Physiology and Pathophysiology |
| Q34411233 | Eurycoma longifolia upregulates osteoprotegerin gene expression in androgen- deficient osteoporosis rat model |
| Q33816762 | For and against: The male menopause--does it exist? |
| Q37563995 | Fracture prevention in men. |
| Q36618559 | Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. |
| Q43843500 | Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. |
| Q33687471 | High-throughput screening of a small molecule library for promoters and inhibitors of mesenchymal stem cell osteogenic differentiation. |
| Q34280203 | Hormonal changes in aging men: a therapeutic indication? |
| Q33569163 | Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? |
| Q45442800 | Human immunodeficiency virus and hypogonadal bone disease |
| Q45229175 | Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life |
| Q35852422 | Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy |
| Q33343391 | IGF-I improved bone mineral density and body composition of weaver mutant mice |
| Q37299250 | ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males |
| Q38169799 | Influence of sex steroids on inflammation and bone metabolism |
| Q43737816 | Inverse association between bone turnover rate and bone mineral density in community-dwelling men >70 years of age: no major role of sex steroid status |
| Q37310024 | Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations |
| Q90600742 | Is Testosterone Replacement Therapy in Older Men Effective and Safe? |
| Q50886876 | Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men. |
| Q37135281 | Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. |
| Q37709720 | Klinefelter's syndrome, type 2 diabetes and the metabolic syndrome: the impact of body composition. |
| Q91620791 | LIN28B affects gene expression at the hypothalamic-pituitary axis and serum testosterone levels |
| Q34396808 | Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment |
| Q51764565 | Lessons from the Testosterone Trials. |
| Q35692900 | Male hypogonadism in the primary care clinic |
| Q37866630 | Male late-onset hypogonadism: pathogenesis, diagnosis and treatment |
| Q36255238 | Male osteoporosis: new trends in diagnosis and therapy |
| Q37337113 | Management of osteoporosis in the aging male: focus on zoledronic acid |
| Q35117241 | Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan |
| Q37597592 | Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction |
| Q44136626 | Monitoring bone density in hypogonadal men by quantitative phalangeal ultrasound |
| Q34380984 | Neuroendocrine aging in men. Andropause and somatopause |
| Q33897266 | Novel double-layer Silastic testicular prosthesis with controlled release of testosterone in vitro, and its effects on castrated rats |
| Q84583168 | Novel strategies for improving physical function |
| Q33976165 | Off-label use of hormones as an antiaging strategy: a review |
| Q37900796 | Onset of effects of testosterone treatment and time span until maximum effects are achieved |
| Q57244901 | Osteoporosis in Men |
| Q56110001 | Osteoporosis in men |
| Q77322332 | Osteoporosis in men |
| Q85708451 | Osteoporosis in men |
| Q88549953 | Osteoporosis in men |
| Q34250920 | Osteoporosis in men: are we ready to diagnose and treat? |
| Q35680543 | Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment |
| Q46446900 | Osteoporosis in men: epidemiology, physiopathology, diagnosis, prevention and treatment |
| Q38077109 | Osteoporosis in men: recent progress |
| Q44960195 | Osteoporosis in men: the value of laboratory testing |
| Q74156843 | Osteoporosis in older men |
| Q34034405 | Osteoporosis. Pathogenesis, diagnosis, and treatment in older adults |
| Q26864777 | Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology |
| Q92419205 | Paediatric and adult-onset male hypogonadism |
| Q36824450 | Patient assessment in the diagnosis, prevention, and treatment of osteoporosis |
| Q24791116 | Preliminary development of a new individualised questionnaire measuring quality of life in older men with age-related hormonal decline: the A-RHDQoL |
| Q37618825 | Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years |
| Q37085390 | Recent topics related to testosterone deficiency syndrome in Japan |
| Q36979941 | Recent trends in the treatment of testosterone deficiency syndrome |
| Q36387995 | Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men. |
| Q37498164 | Risks of testosterone replacement therapy in men. |
| Q55519929 | Selective Androgen Receptor Modulators as Function Promoting Therapies. |
| Q35188685 | Sex hormones and male health: effects on components of the frailty syndrome |
| Q37130045 | Sex hormones, their receptors and bone health |
| Q92694532 | Testosterone and Dehydroepiandrosterone Treatment in Ageing Men: Are We All Set? |
| Q34417734 | Testosterone and growth hormone normalization: a retrospective study of health outcomes. |
| Q35076387 | Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? |
| Q26770414 | Testosterone deficiency in the aging male |
| Q24647679 | Testosterone for the aging male; current evidence and recommended practice |
| Q28244508 | Testosterone hormone replacement therapy: state-of-the-art and emerging technologies |
| Q34995426 | Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects |
| Q36487406 | Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle |
| Q38439191 | Testosterone replacement and bone mineral density in male pituitary tumor patients |
| Q37980121 | Testosterone replacement in male hypogonadism |
| Q80297537 | Testosterone replacement in men with andropause: an overview |
| Q37673421 | Testosterone replacement therapy and bone mineral density in men with hypogonadism |
| Q80562148 | Testosterone replacement therapy for older men |
| Q38634958 | Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism |
| Q35195115 | Testosterone replacement therapy in male hypogonadism |
| Q34676945 | Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. |
| Q37218685 | Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review |
| Q28068397 | Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return? |
| Q28258718 | Testosterone treatment comes of age: new options for hypogonadal men |
| Q46595277 | Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. |
| Q34276276 | The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. |
| Q48490031 | The androgen-deficient aging male: current treatment options. |
| Q34071885 | The anorexia of aging |
| Q36755298 | The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing |
| Q38180392 | The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis |
| Q90130489 | The effects of testosterone on bone health in males with testosterone deficiency: a systematic review and meta-analysis |
| Q33727918 | The male menopause: does it exist?: against: problems of senescence in men are not analogous to female menopause |
| Q36625952 | The need for increasing awareness of osteoporosis in men. |
| Q73920240 | The relation between bone density, free androgen index, and estradiol in men 60 to 70 years old |
| Q37145218 | The role of testosterone in the pathogenesis of prostate cancer |
| Q26795519 | The treatment of late-onset hypogonadism |
| Q53704952 | Therapist-Assisted Progressive Resistance Training, Protein Supplements, and Testosterone Injections in Frail Older Men with Testosterone Deficiency: Protocol for a Randomized Placebo-Controlled Trial. |
| Q38212063 | To treat or not to treat with testosterone replacement therapy: a contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer |
| Q36564415 | Towards a diagnostic and therapeutic consensus in male osteoporosis |
| Q36139976 | Treatment of Men for "Low Testosterone": A Systematic Review |
| Q35895418 | Treatment of osteoporosis in men. |
| Q47571312 | Trials of testosterone replacement reporting cardiovascular adverse events |
| Q57450309 | Weekly Oral Alendronic Acid in Male Osteoporosis |
Search more.